Evidence map›Paper›PMID 38289531›Full record

ArticleJournal of neuro-oncology2024

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

L Gately, C Mesía, J M Sepúlveda, S Del Barco, E Pineda, R Gironés, J Fuster, W Hong, M Dumas, S Gill and 28 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors.

L GatelyPersonalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. gately.l@wehi.edu.au.
C MesíaMedical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain.
J M SepúlvedaMedical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
S Del BarcoMedical Oncology Service, Institut Català d'Oncologia Girona, Girona, Spain.
E PinedaMedical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain.
R GironésMedical Oncology Service, Hospital Universitario La Fe, Valencia, Spain.
J FusterMedical Oncology Service, Hospital Son Espases, Palma de Mallorca, Spain.
W HongPersonalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
M DumasPersonalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
S GillDepartment of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
L M NavarroMedical Oncology Service, Hospital de Salamanca, Salamanca, Spain.
A HerreroMedical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain.
A DowlingDepartment of Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
R de Las PeñasMedical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain.
M A VazMedical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain.
M AlonsoMedical Oncology Service, Hospital Virgen del Rocio, Seville, Spain.
Z LwinDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
R HarrupDepartment of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia.
S PeraltaMedical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain.
A LongDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
P Perez-SeguraMedical Oncology Service, Hospital Clinico San Carlos, Madrid, Spain.
E AhernDepartment of Medical Oncology, Monash Health, Melbourne, VIC, Australia.
C O GarateMedical Oncology Service, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.
M WongDepartment of Medical Oncology, Westmead Hospital, Westmead, NSW, Australia.
R CampbellDepartment of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia.
K CuffDepartment of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
R JennensDepartment of Medical Oncology, Epworth Health, Richmond, VIC, Australia.
O GallegoMedical Oncology Service, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
C UnderhillDepartment of Medical Oncology, Border Medical Oncology, East Albury, NSW, Australia.
M Martinez-GarciaMedical Oncology Service, Hospital del Mar, Barcelona, Spain.
M CovelaMedical Oncology Service, Hospital Lucus Augusti, Lugo, Spain.
A CooperDepartment of Medical Oncology, Liverpool Hospital, Liverpool, NSW, Australia.
S BrownDepartment of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia.
M RosenthalDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
J TorresDepartment of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia.
I M CollinsDepartment of Medical Oncology, South West Regional Cancer Centre, Geelong, VIC, Australia.
P GibbsPersonalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
C BalanaMedical Oncology Service, Institut Català d'Oncologia, Badalona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38289531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.